Article Information
History
- March 19, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Douglas P. Loesch1,*,
- Manik Garg1,
- Dorota Matelska1,
- Dimitrios Vitsios1,
- Xiao Jiang1,
- Scott C. Ritchie2,3,4,5,6,
- Benjamin B. Sun7,
- Heiko Runz7,
- Christopher D. Whelan8,
- Rury R. Holman9,
- Robert J. Mentz10,
- Filipe A. Moura11,
- Stephen D. Wiviott11,
- Marc S. Sabatine11,
- Miriam S. Udler12,13,14,
- Ingrid A. Gause-Nilsson15,
- Slavé Petrovski1,
- Jan Oscarsson15,
- Abhishek Nag1,#,
- Dirk S. Paul1,*,# and
- Michael Inouye2,3,4,5,6,16,#
- 1Centre for Genomics Research, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
- 2British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
- 3Victor Phillip Dahdaleh Heart and Lung Research Institute, University of Cambridge, Cambridge UK
- 4British Heart Foundation Centre of Research Excellence, University of Cambridge, Cambridge, UK
- 5Health Data Research UK Cambridge, Wellcome Genome Campus and University of Cambridge, Cambridge, UK
- 6Cambridge Baker Systems Genomics Initiative, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
- 7Translational Sciences, Biogen Inc., Cambridge, MA, USA
- 8Data Science, Janssen Pharmaceuticals, Princeton, NJ, USA
- 9Diabetes Trials Unit, Radcliffe Department of Medicine, University of Oxford, Oxford, UK
- 10Division of Cardiology, Duke University School of Medicine, Durham, NC, USA
- 11Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA
- 12Diabetes Unit, Massachusetts General Hospital, Boston, Massachusetts, USA
- 13Center for Genomic Medicine, Massachusetts General Hospital, Boston, Massachusetts, USA
- 14Broad Institute of MIT and Harvard, Cambridge, Massachusetts, USA. Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA
- 15Late-Stage Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
- 16Cambridge Baker Systems Genomics Initiative, Baker Heart and Diabetes Institute, 75 Commercial Rd, Melbourne 3004, Victoria, Australia
- ↵*Correspondence: Douglas Loesch, douglas.loesch{at}astrazeneca.com; Dirk S. Paul, dirk.paul{at}astrazeneca.com
Posted March 19, 2024.
Identification of plasma proteomic markers underlying polygenic risk of type 2 diabetes and related comorbidities
